Free public records show Ocular Therapeutix, Inc. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Ocular Therapeutix, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1393434. Retrieved 13 Nov 2026.
4 active studies led by Ocular Therapeutix, Inc., of 33 in all
Source: ClinicalTrials.gov, Studies with Ocular Therapeutix, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
1 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
1 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1393434.
Studies Ocular Therapeutix, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Ocular Therapeutix, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Ocular Therapeutix, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Ocular Therapeutix, Inc. is in.
Stories on the topics Ocular Therapeutix, Inc. works in.
Search all reports for Ocular Therapeutix, Inc. All companies
